Zura Bio
Robert Lisicki is the President and Chief Operating Officer at Zura Bio Limited. He also serves as a Member of the Board of Directors at Adiso Therapeutics and Cadrenal Therapeutics, Inc. With a background in various pharmaceutical companies, Lisicki has extensive experience in global scaling, development of novel agents, and P&L accountability. His expertise spans across different areas such as auto-immune conditions, cardiovascular diseases, and rare genetic disorders.
Zura Bio
1 followers
Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA.